Neuroendocrine Neoplasia incidence, survival and health economics
Research type
Research Study
Full title
Determine mode of presentation, route to diagnosis, updated incidence, prevalence and survival of patients with Neuroendocrine Neoplasia, calculating total costs of care
IRAS ID
284875
Contact name
Benjamin White
Contact email
Sponsor organisation
Hampshire Hospitals NHS Foundatin Trust
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Neuroendocrine neoplasias (NEN) are a rare type of cancer which are becoming more common year-on-year worldwide. In the most recent data, NEN is now more common than stomach and pancreas cancer.
Over the years, the internationally agreed definition of this type of cancer has evolved to become more sophisticated. In 2017 the World Health Organisation (WHO) updated its classification of NEN which allows people to collect and study the data in more detail. In England, the data is derived from pathology specimens and is held in an anonymised form by Public Health England in the National Cancer Registry and Analysis Service (NCRAS).
Using data from NCRAS, we aim to study how common these cancers have become across age groups and also analyse other important factors such as sex, additional health problems, geographic area and deprivation. We will look at how people are being diagnosed with the tumours (such as via their GP or via A&E) and how long it takes. Using health economic analysis methods we can also use the data to calculate the cost of caring for those with NEN in England.
The results of this study will be of interest and provide important information to patients who have the disease, public health departments in the UK and NHS England, NEN multidisciplinary meetings, Neuroendocrine Cancer UK (charitable organisation), medical societies and healthcare professionals.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
20/NW/0342
Date of REC Opinion
21 Jul 2020
REC opinion
Favourable Opinion